13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The spinal and cerebral profile of adult spinal-muscular atrophy: A multimodal imaging study

      research-article
      a , 1 , a , b , 1 , c , d , e , e , c , f , g , c , h , c , c , a , c , i , c , j , k , l , m , n , u , o , a , p , c , q , a , a , r , a , c , s , 2 , a , c , t , * , 2
      NeuroImage : Clinical
      Elsevier
      Spinal muscular atrophy, SMA, Multimodal MRI, Spinal cord MRI, Grey matter and white matter degeneration, 6MWT, Six-minute walk test, AD, Axial diffusivity, ALS, Amyotrophic lateral sclerosis, CSA, cross-sectional area, CST, Corticospinal tract, DTI, diffusion tensor imaging, EPI, Echo-planar imaging, FA, Fractional anisotropy, FDR, False discovery rate, FOV, Field-of-view, FWE, Familywise error, GM, Grey matter, HC, Healthy control, LL, Lower limb, LMN, Lower motor neuron, MD, mean diffusivity, MND, Motor neuron disease, MNI, Montreal Neurological Institute, MRC, Medical Research Council, RD, Radial diffusivity, ROI, Region-of-interest, SC, Spinal cord, SMA, Spinal muscular atrophy, SMAFRS, SMA functional rating scale, SMN1, Survival-motor-neuron 1 gene, TBSS, Tract-based spatial statistics, TE, Echo time, TFCE, Threshold-free cluster enhancement, TR, repetition time, UL, Upper limb, UMN, Upper motor neuron, VBM, Voxel-based morphometry, WM, White matter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Spinal muscular atrophy (SMA) type III and IV are autosomal recessive, slowly progressive lower motor neuron syndromes. Nevertheless, wider cerebral involvement has been consistently reported in mouse models. The objective of this study is the characterisation of spinal and cerebral pathology in adult forms of SMA using multimodal quantitative imaging.

          Methods

          Twenty-five type III and IV adult SMA patients and 25 age-matched healthy controls were enrolled in a spinal cord and brain imaging study. Structural measures of grey and white matter involvement and diffusion parameters of white matter integrity were evaluated at each cervical spinal level. Whole-brain and region-of-interest analyses were also conducted in the brain to explore cortical thickness, grey matter density and tract-based white matter alterations.

          Results

          In the spinal cord, considerable grey matter atrophy was detected between C2-C6 vertebral levels. In the brain, increased grey matter density was detected in motor and extra-motor regions of SMA patients. No white matter pathology was identified neither at brain and spinal level.

          Conclusions

          Adult forms of SMA are associated with selective grey matter degeneration in the spinal cord with preserved white matter integrity. The observed increased grey matter density in the motor cortex may represent adaptive reorganisation.

          Highlights

          • (SMA) type 3 and 4 is a lower motor neuron syndrome. Nevertheless, wider involvement of the nervous system might be possible.

          • 25 adults type 3 and 4 SMA patients were studied using brain and cervical spinal cord neuroimaging techniques.

          • Grey matter atrophy was observed in the spinal cord. No white matter degeneration was present at brain and spinal level.

          • Increased grey matter density was detected in cerebral motor regions and explained as compensatory mechanism.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing.

          The survival of motor neurons (SMN) protein is essential for the biogenesis of small nuclear RNA (snRNA)-ribonucleoproteins (snRNPs), the major components of the pre-mRNA splicing machinery. Though it is ubiquitously expressed, SMN deficiency causes the motor neuron degenerative disease spinal muscular atrophy (SMA). We show here that SMN deficiency, similar to that which occurs in severe SMA, has unexpected cell type-specific effects on the repertoire of snRNAs and mRNAs. It alters the stoichiometry of snRNAs and causes widespread pre-mRNA splicing defects in numerous transcripts of diverse genes, preferentially those containing a large number of introns, in SMN-deficient mouse tissues. These findings reveal a key role for the SMN complex in RNA metabolism and in splicing regulation and indicate that SMA is a general splicing disease that is not restricted to motor neurons.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4.

            Natural history studies in spinal muscular atrophy (SMA) have primarily focused on infants and children. Natural history studies encompassing all age groups and SMA types are important for the interpretation of treatment effects of recently introduced survival motor neuron gene-augmenting therapies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Spinal muscular atrophy--recent therapeutic advances for an old challenge.

              In the past decade, improved understanding of spinal muscular atrophy (SMA) aetiopathogenesis has brought us to a historical turning point: we are at the verge of development of disease-modifying treatments for this hitherto incurable disease. The increasingly precise delineation of molecular targets within the survival of motor neuron (SMN) gene locus has led to the development of promising therapeutic strategies. These novel avenues in treatment for SMA include gene therapy, molecular therapy with antisense oligonucleotides, and small molecules that aim to increase expression of SMN protein. Stem cell studies of SMA have provided an in vitro model for SMA, and stem cell transplantation could be used as a complementary strategy with a potential to treat the symptomatic phases of the disease. Here, we provide an overview of established data and novel insights into SMA pathogenesis, including discussion of the crucial function of the SMN protein. Preclinical evidence and recent advances from ongoing clinical trials are thoroughly reviewed. The final remarks are dedicated to future clinical perspectives in this rapidly evolving field, with a broad discussion on the comparison between the outlined therapeutic approaches and the remaining open questions.
                Bookmark

                Author and article information

                Contributors
                Journal
                Neuroimage Clin
                Neuroimage Clin
                NeuroImage : Clinical
                Elsevier
                2213-1582
                28 November 2018
                2019
                28 November 2018
                : 21
                : 101618
                Affiliations
                [a ]Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Paris, France
                [b ]Icahn School of Medicine at Mount Sinai, Department of Neurology, New York, USA
                [c ]APHP, Département de Neurologie, Hôpital Pitié-Salpêtrière, Centre référent SLA, Paris, France
                [d ]APHP, Hôpital Pitié-Salpêtriere, Service d'Explorations Fonctionnelles, Paris, France
                [e ]APHP, Centre de Référence Maladies Neuromusculaires Paris-Est, Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France
                [f ]Department of Neurology, ALS Centre, Lille University, INSERM UMRS_1171, University Hospital Centre, LICEND COEN Centre, Lille, France
                [g ]Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Centre, LICEND COEN Centre, Lille, France
                [h ]Département de recherche en éthique, EA 1610: Etudes des sciences et techniques, Université Paris Sud/Paris Saclay, Paris, France
                [i ]Hôpital des Peupliers, Ramsay Générale de Santé, F-75013 Paris, France
                [j ]NeuroPoly Lab, Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, QC, Canada
                [k ]Functional Neuroimaging Unit, CRIUGM, Université de Montréal, Montreal, QC, Canada
                [l ]APHP, Hôpital Pitié-Salpêtriere, Service de Neuroradiologie, Paris, France
                [m ]Sorbonne Université, UMR-S975, Inserm U975, CNRS UMR7225, Centre de recherche de l'Institut du Cerveau et de la Moelle épinière – CRICM, Centre de Neuroimagerie de Recherche – CENIR, Paris, France
                [n ]Neurology Department, Nord/Est/Ile de France neuromuscular center, Raymond-Poincaré Hospital, Garches, France
                [o ]Institut pour la Recherche sur la Moelle Epinière et l'Encéphale (IRME), Paris, France
                [p ]Concordia University, PERFORM Centre, Electrical & Computer Engineering Division, Canada
                [q ]Sorbonne Université, CNRS UMR7622, INSERM ERL 1156, IBPS, Paris, France
                [r ]Institute of Myology, Neuromuscular Investigation Center, Paris, France
                [s ]Computational Neuroimaging Group, Academic Unit of Neurology, Trinity College Dublin, Ireland
                [t ]Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute Ulster University, C-TRIC, Altnagelvin Hospital, Derry, Londonderry, United Kingdom
                [u ]INSERM U1179, END-ICAP, Versailles Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux
                Author notes
                [* ]Corresponding author at: Département de Neurologie, 47 Boulevard de l'Hôpital, F-75634, Cedex 13, France. pierre-francois.pradat@ 123456aphp.fr
                [1]

                Contributed equally as first co-authors.

                [2]

                Contributed equally as senior co-authors.

                Article
                S2213-1582(18)30366-8 101618
                10.1016/j.nicl.2018.101618
                6413472
                30522974
                b8bf4359-5511-42dd-a425-f4b7873a8049
                © 2018 The Authors

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 8 September 2018
                : 17 November 2018
                : 26 November 2018
                Categories
                Article

                spinal muscular atrophy,sma,multimodal mri,spinal cord mri,grey matter and white matter degeneration,6mwt, six-minute walk test,ad, axial diffusivity,als, amyotrophic lateral sclerosis,csa, cross-sectional area,cst, corticospinal tract,dti, diffusion tensor imaging,epi, echo-planar imaging,fa, fractional anisotropy,fdr, false discovery rate,fov, field-of-view,fwe, familywise error,gm, grey matter,hc, healthy control,ll, lower limb,lmn, lower motor neuron,md, mean diffusivity,mnd, motor neuron disease,mni, montreal neurological institute,mrc, medical research council,rd, radial diffusivity,roi, region-of-interest,sc, spinal cord,sma, spinal muscular atrophy,smafrs, sma functional rating scale,smn1, survival-motor-neuron 1 gene,tbss, tract-based spatial statistics,te, echo time,tfce, threshold-free cluster enhancement,tr, repetition time,ul, upper limb,umn, upper motor neuron,vbm, voxel-based morphometry,wm, white matter

                Comments

                Comment on this article